Drug intelligence / Profile preview

6-hydroxy-5-undecyl-4,7-benzothiazoledione

Development stage: Unknown
Modality: Small Molecules

Overview

6-Hydroxy-5-undecyl-4,7-benzothiazoledione (UHDBT) is an experimental small molecule compound with the molecular formula C18H25NO3S and a molecular weight of approximately 335.46 g/mol[1][2][8]. It belongs to the benzothiazole class of organic compounds and is also classified as an organoheterocyclic compound[3][5]. The drug has not been approved for any indication in the US or elsewhere and has no reported clinical trials beyond preclinical or experimental stages[1]. Its mechanism of action and therapeutic applications are not well characterized in public databases. There is no evidence it has reached clinical development for any disease.

Other names: 5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole6-hydroxy-5-undecyl-1,3-benzothiazole-4,7-dione43152-58-5

Beyond the preview

Go deeper on 6-hydroxy-5-undecyl-4,7-benzothiazoledione.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 6-hydroxy-5-undecyl-4,7-benzothiazoledione.

Explore the full profile